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SLC2A3 encodes the predominantly neuronal glucose transporter 3 (GLUT3), which
facilitates diffusion of glucose across plasma membranes. The human brain depends
on a steady glucose supply for ATP generation, which consequently fuels critical
biochemical processes, such as axonal transport and neurotransmitter release.
Besides its role in the central nervous system, GLUT3 is also expressed in nonneural
organs, such as the heart and white blood cells, where it is equally involved in energy
metabolism. In cancer cells, GLUT3 overexpression contributes to the Warburg ef-
fect by answering the cell's increased glycolytic demands. The SLC2A3 gene locus at
chromosome 12p13.31 is unstable and prone to non‐allelic homologous re-
combination events, generating multiple copy number variants (CNVs) of SLC2A3
which account for alterations in SLC2A3 expression. Recent associations of SLC2A3
CNVs with different clinical phenotypes warrant investigation of the potential in-
fluence of these structural variants on pathomechanisms of neuropsychiatric, car-
diovascular, and immune diseases. In this review, we accumulate and discuss the
evidence how SLC2A3 gene dosage may exert diverse protective or detrimental
effects depending on the pathological condition. Cellular states which lead to
increased energetic demand, such as organ development, proliferation, and cellular
degeneration, appear particularly susceptible to alterations in SLC2A3 copy number.
We conclude that better understanding of the impact of SLC2A3 variation on disease
etiology may potentially provide novel therapeutic approaches specifically targeting
this GLUT.
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1 | INTRODUCTION
1.1 | Carbohydrate metabolism
Carbohydrates are the major source of energy in humans. Carbohy-
drate intake, digestion, absorption and eventual distribution requires a
well‐balanced interplay between glycolytic and gluconeogenic hor-
mones. For healthy individuals, this results in a relatively narrow range
of plasma glucose levels, in order to protect cells from the toxic effects
of hyperglycemia and life‐threatening hypoglycemia. Before glucose
can be used as an electron donor in glycolysis, it must be carried across
the plasma membrane. The highly hydrophilic glucose molecule cannot
enter cells passively, and therefore specific transmembrane glucose
transporters (GLUTs) have evolved in all metazoan species, with a high
grade of genetic conservation (Jia, Yuan, Lan, Xuan, & Jeon, 2019).
Sodium glucose transporters (SGLTs) exhibit a secondary active
transport mechanism. However, transport via GLUTs utilizes the
electrochemical gradient of glucose to facilitate diffusion in an energy‐
independent manner. Whereas SGLTs are expressed for the sole pur-
pose of glucose absorption and reabsorption, particularly in intestinal
cells and renal proximal tubular cells, GLUTs are ubiquitously ex-
pressed throughout the body, with single members of the GLUT‐family
showing differential tissue expression patterns. GLUTs are essential for
glucose homeostasis as they are involved in the control of cellular
glucose uptake and consumption, glucose storage, and hormonal reg-
ulation. Besides their role as cellular gatekeepers, GLUTs have also
been suggested to play a role in glucose sensing, with implications for
fasting glucose levels and diabetes risk (Dupuis et al., 2010).
1.2 | Towards cellular and clinical implications of
SLC2A3 CNVs
Haploinsufficiency of GLUT1 leads to developmental delay, micro-
cephaly, and neurological symptoms, such as epileptic seizures,
spasticity, hypotonia, and complex motor symptoms (De Giorgis &
Veggiotti, 2013). Rare loss‐of‐function mutations in GLUT2, GLUT9,
and GLUT10 are associated with Fanconi‐Bickel syndrome, renal
hypouricemia, and arterial tortuosity syndrome, respectively. These
diseases all follow an autosomal recessive inheritance pattern, and
are due to protein truncation and/or impaired membrane trafficking
of the affected GLUT (Coucke et al., 2006; Matsuo et al., 2008;
Santer et al., 1997). Mutations in the other GLUTs have not been
observed to cause disorders by a Mendelian inheritance mode.
However, in recent studies copy number variants (CNVs) of the
SLC2A3 (GLUT3) gene were associated with the risk for various
clinical phenotypes, such as attention‐deficit/hyperactivity disorder
(ADHD), rheumatoid arthritis (RA), chorea huntington, and congenital
heart defects (Lesch et al., 2011; Mlynarski et al., 2015; Monteiro
et al., 2017; Prakash et al., 2016; Veal et al., 2014; Vittori
et al., 2014). This raises the question of whether there exists a
common disease mechanism in different tissue types, that is depen-
dent on SLC2A3 gene dosage.
In this context, we will first illustrate the unique character-
istics of GLUT3, with emphasis on expression data and experi-
mental manipulation of SLC2A3 gene dosage. Second, we will
highlight the role of GLUT3 in carcinogenesis, and discuss whether
research findings from metabolic cancer research can be trans-
lated into other clinical fields. We will then portray the potential
impact of structural SLC2A3 variation on clinical phenotypes,
focusing on neuropsychiatric, cardiovascular, and immune dis-
eases. Finally, we will suggest future research to determine the
effects of structural SLC2A3 variation, and propose hypotheses
regarding protective and detrimental consequences of SLC2A3
duplication and deletion events.
2 | THE GLUCOSE TRANSPORTER GLUT3
The SLC2A family of GLUTs comprises 14 members, designated
SLC2A1‐SLC2A12, the myoinositol transporter HMIT (SLC2A13), and
SLC2A14. GLUT3 is encoded by the SLC2A3 gene which is located at
chromosome 12p13.31. Cloning of SLC2A3 was achieved by Kayano
et al. (1988) using a complementary DNA library derived from fetal
skeletal muscle. Consistent with other GLUTs, GLUT3 contains
12 transmembrane domains with both the amino‐ and the carbox-
yterminus located intracellularly, and carries a glycosylation site at
the first extracellular loop (Augustin, 2010). The transmembrane
protein comprises 496 amino acids accounting for a molecular weight
of 54 kDa. GLUT3 has a high affinity (Km = 1.4) for its main substrate
D‐glucose (Colville, Seatter, Jess, Gould, & Thomas, 1993), but also
has the capacity to transport galactose, mannose and ascorbic acid in
vitro (Gould, Thomas, Jess, & Bell, 1991; Rumsey et al., 1997).
A general overview of GLUT3 structure, kinetics and expression
patterns is given by Simpson et al. (2008).
2.1 | SLC2A3 copy number variation
It is thought that several duplication events took place during the
evolution of the SLC2A family, creating novel GLUT genes with dis-
tinct properties regarding tissue and substrate specificity; however,
several functional motifs have been highly conserved (Wilson‐
O'Brien, Patron, & Rogers, 2010). The detection of copy number
variants among the GLUT genes (including SLC2A3) suggests that
these recombination events are still occurring, accounting for both
gene duplications and deletions. The detected structural variants
around the SLC2A3 locus span 122–142 kb (range: chr.12:
7,987,761–8,129,708, hg19, own data) and comprise the entire
SLC2A3 gene, the pseudogene NANOGP1, and the first two exons of
SLC2A14 according to the gene structure published by Wu and
Freeze (2002). As previously reported (Merker et al., 2017), our
comparative genomic hybridization array data showed that chro-
mosomal breakpoints were located in segmental duplications with
high sequence similarity (first duplicon at chr12:7995630–7998390,
second duplicon at chr12:8124315‐8128199; fraction matching
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0.92). It therefore appears that non‐allelic homologous recombina-
tion (NAHR) is the most likely cause of SLC2A3 CNVs.
It is widely accepted that SLC2A14 evolved from a duplication
of SLC2A3, and is therefore the youngest member of the SLC2A‐
family of GLUTs (Augustin, 2010; Mueckler & Thorens, 2013;
Scheepers, Joost, & Schurmann, 2004; Wu & Freeze, 2002).
However, a recent BLAST search has led us to conclude that, it is
actually the other way around; SLC2A3 and NANOGP1 evolved by a
NAHR event that led to duplication of SLC2A14 and NANOG ap-
proximately 29 million years ago, in the common ancestor Old
World monkeys (Figure 1). The newly evolved SLC2A3 gene then
has assumed the role of a high‐affinity transporter for tissues with
elevated glucose demand, whereas the phylogenetically older
SLC2A14 gene appears to play a specialized role in the testis (Wu &
Freeze, 2002). This view is supported by extensive sequence
similarities between the NANOG gene and its numerous pseudo-
genes, amongst which NANOGP1 is one of the youngest (Fairbanks
& Maughan, 2006). Under the assumption of NAHR with
subsequent tandem duplications, only NANOG/SLC2A14 or
SLC2A3/NANOGP1 can represent the true ancestral gene combi-
nation (Figure 1). It is therefore highly unlikely that SLC2A14 and
NANOGP1 originated from the same duplication event. As
SLC2A14 expression is limited to a few specific tissues (Shaghaghi,
Murphy, & Eck, 2016), and NANOGP1 is classified as a pseudogene,
the SLC2A3 gene is of main clinical interest.
A meta‐analysis containing 37,661 control subjects from differ-
ent populations observed a SLC2A3 duplication frequency of 3.44%
and deletion frequency of 0.79% (Table 1), suggesting that the
SLC2A3 duplication is a common structural variant (>1%) whereas
the SLC2A3 deletion is a rare variant (<1%). The different frequencies
between duplication and deletion variants is likely due to a lower
survival rate of embryos carrying a heterozygous deletion, as seen in
rodents (Ganguly et al., 2007). This supports the hypothesis that
duplications are generally under less selection pressure than dele-
tions (Zarrei, MacDonald, Merico, & Scherer, 2015). To date, the
highest SLC2A3 gene copy number ourselves and others have
F IGURE 1 Evolution of SLC2A3 and SLC2A3 CNVs. (a) Genealogical tree of SLC2A3 evolution in human ancestors. (b) Evolution of SLC2A3 by
NAHR. (c) Emergence of SLC2A3 CNVs. In contrast to the common hypothesis that SLC2A14 evolved from SLC2A3 by a duplication event, and is
the phylogenetically youngest member of the GLUT family, SLC2A3 together with NANOGP1 can be considered as the more recent sequences. A
NAHR duplication event in the common ancestor (Catarrhini) of old world monkeys created a copy of SLC2A14 approximately 29 million years
ago (blue star). This copy became expressed in brain and other structures and received the name SLC2A3. Due to the segment order, the new
sequence appears more prone to duplication events as can be seen in the gibbon genome, where the duplication of SLC2A3 was integrated
permanently (lower gray star), or in humans with the CNV (red star). Independent of the old world lineage, new world monkeys developed a
duplication of the original SLC2A3 circa 18 million years ago (upper gray star). Some species also developed further duplications. CNV, copy
number variant; GLUT, glucose transporter; NAHR, non‐allelic homologous recombination
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detected is four (Vittori et al., 2014). It is likely that heterozygous
loss‐of‐function mutations in SLC2A3 are generally tolerable, as ap-
proximately 1 in 130 people carry only one copy of the gene. This is
supported by statistical evidence demonstrating a low probability of
being loss‐of‐function intolerant (probability of being loss‐of‐function
intolerant [pLI] score = 0.01, gnomad.broadinstitute.org). Considering
the embryonal abortion of Glut3 null mice (Schmidt et al., 2009), and
that no humans with zero SLC2A3 copies have been identified so far,
we can infer that homozygous LOF mutations of SLC2A3, though, are
incompatible with life.
2.2 | Physiological regulation of GLUT3 expression
and function
SLC2A3 is most highly expressed in the brain, leading to its unofficial
title of “neuronal glucose transporter”. However, SLC2A3 is also ex-
pressed in other human tissues, such as cardiomyocytes, testis,
spermatozoa, placenta, and white blood cells (Haber, Weinstein,
O'Boyle, & Morgello, 1993; Kipmen‐Korgun, Bilmen‐Sarikcioglu,
Altunbas, Demir, & Korgun, 2009; Shepherd et al., 1992). In the hu-
man brain, GLUT3 seems to be mainly localized to axonal and den-
dritic processes both in the neocortex and in deeper cortical
structures (Mantych, James, Chung, & Devaskar, 1992), suggesting an
important role for GLUT3 in ATP‐dependent axonal transport pro-
cesses and synaptic plasticity. In ultrastructural studies of rodent
brain tissue, subcellular localization of GLUT3 to cellular processes of
the neuropil but also cell bodies has been observed (Fields, Rinaman,
& Devaskar, 1999; Leino, Gerhart, van Bueren, McCall, &
Drewes, 1997). Both in the mouse and rat brain, highest GLUT3
expression can be found in hippocampal regions, Purkinje cells of the
cerebellum, nuclear regions of the brain stem, and the neocortex
(Bondy, Lee, & Zhou, 1992; Nagamatsu et al., 1992). SLC2A3 ex-
pression is not only tissue‐specific, but also inducible. Metabolic,
hormonal, medicinal and toxic factors can trigger an induction and/or
suppression of SLC2A3 expression, which has been particularly ob-
served under hypoglycemic and hypoxic conditions (Korgun
et al., 2002; Wood, Wang, Lorente‐Cebrian, & Trayhurn, 2007). Such
regulation can enable potent upregulation or downregulation of gene
expression, depending on the specific conditions and consequent
energy demand. For example, the transcription factor hypoxia‐in-
ducible factor 1α (HIF1α) can upregulate SLC2A3 gene expression
during hypoxia to facilitate sufficient increased glucose supply
(Baumann, Zamudio, & Illsley, 2007; Thamotharan, Raychaudhuri,
Tomi, Shin, & Devaskar, 2013). Additionally, HIF1α can be activated
by phosphoinositide 3‐kinase (PI3K)/Akt signaling upon binding
of epidermal growth factor (EGF) and insulin‐like growth factor 1
(IGF‐1) at their respective receptors (Figure 2; Kamei et al., 1999; Yu
et al., 2012). The Km of GLUT3 is relatively low, leading to rapid
saturation of its transport capacity in normoglycemic conditions,
yet preserving transporter function in hypoglycemic conditions
with a half‐maximum reaction rate at 25mg/dl blood glucose (Colville
et al., 1993).
Energy‐dependent glucose uptake can be fine‐tuned by translo-
cation of GLUT3 protein from intracellular vesicles to the plasma
membrane. Although GLUT3 is generally considered an insulin‐in-
dependent GLUT, multiple studies have suggested that insulin can
trigger GLUT3 translocation in human leukocytes and rat neurons
(Piatkiewicz, Czech, Taton, & Gorski, 2010; Uemura & Green-
lee, 2006). GLUT3 protein has also been identified in the mitochon-
drial membrane of neuronal cell lines and PC12‐cells (Leino
et al., 1997; Thoidis et al., 1999), as well as in platelet α‐granules,
which migrate to the plasma membrane following thrombin stimu-
lation (Heijnen, Oorschot, Sixma, Slot, & James, 1997). A possible
translocatory mechanism for GLUT3 in cortical and hippocampal
neurons has been proposed; after NMDA receptor binding calcium
influx leads to activation of the NO‐synthase pathway, with con-
secutive cGMP production followed by fusion of GLUT3 containing
TABLE 1 Meta‐analysis of SLC2A3 duplication (gain) and deletion (loss) frequency
n Gain Gain (%) Loss Loss (%) Population
Pinto et al. (2007) 776 15 1.93 4 0.52 Mixed
Jakobsson et al. (2008) 485 14 2.89 2 0.41 Mixed
Shaikh et al. (2009) 2,026 56 2.76 9 0.44 Mixed
Vogler et al. (2010) 1,109 31 2.80 5 0.45 Mixed
Suktitipat et al. (2014) 3,017 75 2.49 8 0.27 Asian
Cooper et al. (2011) 8,329 143 1.72 62 0.74 Mixed
Veal et al. (2014) 1,269 55 4.33 33 2.60 Caucasian
Merker et al. (2017) 1,721 68 3.95 19 1.10 Caucasian
Simpfendorfer et al. (2019) 18,929 839 4.39 155 0.86 Mixed
37,661 1296 3.44 297 0.79
SLC2A3 CNV data from different cohorts of control individuals from mixed populations were gained from the Database of Genomic Variants (http://dgv.
tcag.ca/dgv/app/home). Only studies investigating both duplication and deletion variants were included in the meta‐analysis. In 37,661 individuals from
different populations the mean duplication frequency was 3.44% whereas the mean deletion frequency was 0.79%.
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vesicles with the plasma membrane (Ferreira, Burnett, & Ra-
meau, 2011). Additionally, AMPK activation upon removal of Ca2+ by
ATPases can trigger GLUT3 translocation to the plasma membrane
(Weisova, Concannon, Devocelle, Prehn, & Ward, 2009). This implies
a bidirectional relationship between GLUT3 surface expression and
neurotransmitter release, allowing activity‐dependent regulation of
neuronal glucose transport, potentially aiding synaptic formation, and
excitatory neurotransmission (Figure 3).
In rodents, changes in GLUT3 expression occur concurrently
with crucial steps of organ maturation in the central nervous
system (CNS; Vannucci et al., 1998) and the heart (Grover‐
McKay, Walsh, & Thompson, 1999). These observations support
the hypothesis that adaptive mechanisms of GLUT3 expression
may be advantageous during pre‐ and postnatal developmental
stages, when organ growth coincides with increased energy
demand.
2.3 | Regulation of GLUT3 expression in cancer cells
It is well‐known that malign dedifferentiation is accompanied by
changes in cellular respiration, as originially demonstrated by War-
burg who performed pioneering measurements of oxygen consump-
tion in cancer cells (Warburg, 1956). Healthy cells produce the bulk
of ATP by oxidative phosphorylation (OXPHOS), gaining 36mol of
ATP from only 1mol of glucose. However, cancer cells preferentially
bypass OXPHOS and use glycolysis only, even when enough oxygen
is available as a terminal electron acceptor in the respiratory chain
(aerobic glycolysis; Warburg, 1956). It is still unknown why cancer
cells utilize this less effective method of energy production, which
generates only 2mol of ATP from 1mol of glucose (Hsu & Sabati-
ni, 2008). Warburg postulated that the metabolic shift from OXPHOS
to aerobic glycolysis in cells was the main mechanism of cancer
development (Warburg, 1956).
Currently, glycolytic cancer metabolism is considered an adap-
tation to intracellular alterations, including mitochondrial dysfunc-
tion due to oncogene activation or tumor suppressor loss (King,
Selak, & Gottlieb, 2006). Moreover, rapid proliferation can exceed
the tissue's vascular capacity, meaning that cancer cells often have to
cope with a hypoxic tumor microenvironment in which glycolysis
remains the only feasible option for energy production (Hsu &
Sabatini, 2008). Due to inefficient ATP synthesis from glycolysis, the
cancer cell's glucose demand is considerably elevated.
In support of this, GLUT1 and GLUT3 are overexpressed in many
cancer cells, including tumors of the digestive system (Yamamoto
et al., 1990), extracranial head and neck tumors (Mellanen, Minn,
Grenman, & Harkonen, 1994), and gliomas (Boado, Black, &
Pardridge, 1994). GLUT3 overexpression has additionally been as-
sociated with carcinoma grade and prognosis in non‐small cell lung
cancer (Younes, Brown, Stephenson, Gondo, & Cagle, 1997), lar-
yngeal carcinoma (Baer, Casaubon, Schwartz, Marcogliese, &
Younes, 2002), and oral squamous cell carcinoma (Ayala et al., 2010).
Flavahan et al. (2013) conducted a database search (www.oncomine.
org) which confirmed the correlation between tumor GLUT3 ex-
pression and prognosis in several breast cancer, colorectal carcino-
ma, ovarian cancer, and lung cancer samples. Moreover, the authors
demonstrated the dependence of glioblastoma‐initiating cells on
GLUT3‐mediated glucose uptake, and observed reduced tumor
growth after GLUT3 knockdown (Flavahan et al., 2013). Metastases
of breast and lung cancer exhibit even higher GLUT3 expression than
the underlying primary tumor, further highlighting the potential im-
pact of GLUT3 expression on tumor progression (Kuo et al., 2019;
Kurata, Oguri, Isobe, Ishioka, & Yamakido, 1999). Consequently, the
association of GLUT overexpression with tumor proliferation and
negative survival outcomes has suggested that novel treatment
strategies which aim at starving out tumors by blockade of GLUT‐
mediated glucose uptake may be feasible. Supporting this, there has
been increasing evidence showing antiproliferative and apoptotic
effects of GLUT inhibition in cancer cells (Barron, Bilan, Tsakiridis, &
Tsiani, 2016).
F IGURE 2 Signaling pathways for SLC2A3 and glycolytic
regulation. PI3K/Akt signaling plays a key role for the regulation of
both SLC2A3 expression levels and glycolytic activity by disinhibition
of mTOR via TSC1/2. Consecutively, mTOR activates HIF1α, which
binds hypoxia‐responsive elements (HRE) in the SLC2A3 promotor
region. The PI3K/Akt pathway can be activated by both extrinsic
growth hormones (such as EGF and IGF‐1), and by intrinsic factors
(such as the oncogene Caveolin‐1; Cav‐1) which interacts with
growth hormone receptors. Additionally, Cav‐1 can increase
glycolytic activity via Wnt pathway targeting of the oncogene c‐MYC,
and enhance SLC2A3 transcription by direct nuclear interaction with
the transcription factor HMGA1. Loss of the tumor suppressor gene
p53 during oncogenic transformation leads to increased glycolytic
activity and enhanced SLC2A3 expression levels via NFκB signaling.
This figure was designed in part using Servier Medical ART (https://
smart.servier.com). EGF, epidermal growth factor; HIF1α, hypoxia‐
inducible factor 1α; IGF‐1, insulin‐like growth factor; IKK, IκB kinase;
mTOR, mammalian target of rapamycin; NFκB, nuclear factor κB;
OXPHOS, oxidative phosphorylation; PI3K, phosphoinositide 3‐
kinase; TCA, tricarboxic acid cycle
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The proposed gene‐dose effect of SLC2A3 CNVs on cellular
glucose uptake, and the increased mutation rate in cancer cells
(Jackson, 1998), suggest that SLC2A3 duplications could be enriched
in tumor tissue thereby helping to cover elevated glucose demands.
The observation of increased SLC2A3 duplications in human em-
bryonic stem cell lines (9 out of 69 cell lines; Laurent et al., 2011)
additionally infers an increase of underlying NAHR events in highly
proliferative tissue. Conversely, SLC2A3 deletions may disrupt the
cancer cell's need for glucose, and thereby decelerate tumor growth.
However, to the authors’ knowledge, there are currently no studies
which have investigated an association between SLC2A3 copy num-
ber (intratumoral or inherited) and specific cancers or cancer prog-
nosis. There are also no positive genome‐wide association study
(GWAS) findings in this regard.
Cancer research has provided a multitude of data on the in-
tracellular signaling cascades which control both SLC2A3 expres-
sion levels and activity of glycolytic genes. Converging evidence
points to a direct interaction of oncogenes and tumor suppressor
genes with glucometabolic pathways. The oncogene Caveolin‐1
(Cav‐1) activates the canonical Wnt‐pathway, which in turn targets
the oncogene c‐Myc with a consecutive increase in glycolytic ac-
tivity (Tahir et al., 2013). Nuclear Cav‐1 additionally leads to en-
hanced SLC2A3 expression by facilitating HMGA1 binding in the
SLC2A3 promotor region (Ha & Chi, 2012). Furthermore, Cav‐1
directly interacts with IGF‐1 and insulin receptors, with con-
secutive activation of the PI3K/Akt pathway which boosts the
expression of SLC2A3 and glycolytic genes via mammalian target of
rapamycin (mTOR; Tahir et al., 2013). Loss of the tumor sup-
pressor p53 also leads to heightened glycolytic activity and
SLC2A3 overexpression via nuclear factor κB (Figure 2; Kawauchi,
Araki, Tobiume, & Tanaka, 2008). Thus, the loss of tumor sup-
pressor genes and activation of oncogenes directly regulate the
cancer cell's glucose supply and glycolytic utilization, supporting
the Warburg effect.
F IGURE 3 The role of GLUT3 for excitatory neurotransmission. Glucose crosses the blood‐brain barrier via GLUT1. Lactate, generated by
anaerobic glycolysis in astrocytes, enters neurons with the help of the monocarboxylate transporter MCT2. Neurons can use both lactate and
glucose (which enters the cell by facilitated diffusion via GLUT3) as substrates for oxidative phosphorylation for mitochondrial ATP generation.
ATP is necessary for energy‐dependent assembly of synaptic vesicles in the presynaptic terminal and is additionally used as cotransmitter. Upon
arrival of action potentials at the terminal, Ca2+ influx leads to fusion of synaptic vesicles with the presynaptic membrane, and neurotransmitter
release into the synaptic cleft. Glutamate binding at NMDA receptors triggers Ca2+ influx into the postsynaptic neuron. Ca2+ and Akt lead to
phosphorylation of NOS1, evoking translocation of GLUT3‐containing vesicles to the plasma membrane, induced by cyclic GMP‐dependent
protein kinases (cGK). AMP‐dependent kinases (AMPK), which are activated by increased AMP:ATP ratio, can additionally provoke GLUT3
translocation to the plasma membrane. GLUT3‐mediated glucose supply is crucial for the generation of ATP, which is needed for restoration of
resting membrane potential after depolarization during action potential conduction. This figure was designed in part using Servier Medical ART
(https://smart.servier.com). EPSP, excitatory postsynaptic potential; GLUT3, glucose transporter 3
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Even though there is presently no evidence for an association
between SLC2A3 CNVs and cancer or cancer prognosis, the in-
vestigation of glucose metabolism and GLUTs in cancer research has
led to valuable knowledge about the expressional regulation of
GLUT3, which can inform further research on the cellular con-
sequences of SLC2A3 CNVs. Cellular signaling upstream of GLUT3
transcriptional regulation has been well‐characterized for the above
reviewed pathways. However, it is currently unclear whether SLC2A3
CNVs can have gene dosage‐dependent consequences for down-
stream effectors beyond the established glucometabolic processes of
glycolysis and tricarboxic acid cycle (TCA). Therefore, the following
sections are devoted to the consequences of SLC2A3 CNV in cellular
models, and disease associations are discussed.
2.4 | Functional consequences of SLC2A3
expression changes on the cellular level
Studies from mouse and cell culture models have suggested that
SLC2A3 CNVs may have an impact on the cellular level. Hetero-
zygous SLC2A3 knockout (KO) mice showed a decrease in
Slc2A3 messenger RNA (mRNA) and protein expression in whole
brain lysates compared with wild‐type (WT), yet only a small de-
crease in glucose uptake, which coincided with increased GLUT1 and
MCT2 protein (Zhao et al., 2010). Two further studies using het-
erozygous KO models did not find any differences in brain glucose
uptake between WT and Slc2a3+/− mice, despite a 50% decrease in
protein expression (Schmidt et al., 2008; Stuart et al., 2011). One
possible explanation could be compensatory changes in other GLUT
expression, as observed above, but the discrepancy may also po-
tentially be explained by posttranslational translocation of GLUT3. In
the case of reduced whole cell GLUT3, vesicular stores may be de-
pleted first, leaving functional GLUT3 located at the plasma mem-
brane mostly unaffected. However, in the studies described only
whole brain glucose uptake and glucose uptake in astrocytes were
measured, which are both highly dependent on GLUT1 as the major
GLUT in astrocytes and the blood‐brain barrier (Morgello, Uson,
Schwartz, & Haber, 1995). When measuring glucose uptake in cell
models of SLC2A3 CNV in future studies, inhibition of other GLUTs
should be considered, with an inhibitor for GLUT1 already available
(Siebeneicher et al., 2016).
Previous reports have suggested that SLC2A3 duplication in-
creases SLC2A3 mRNA expression by more than 50%; Yang et al.
(2009) described increased SLC2A3 expression of approximately 75%
in human fibroblasts, and in our studies, we found expression in-
creased by 73% in human lymphoblasts and 220% in human leu-
koytes (Merker et al., 2017). Whether GLUT3 protein expression
reflects this increased transcription in duplication carriers remains
controversial. To date, only a single study by Vittori et al. (2014)
found increased protein expression in cell lines from duplication
carriers, whereas we and others did not observe such an effect in
similar experimental settings (Merker et al., 2017; Simpfendorfer
et al., 2019). Furthermore, the duplication variant did not affect
glucose uptake levels in lymphoblastoid cells under basal conditions
(Merker et al., 2017). This discrepancy between mRNA and protein
expression/transport capacity in SLC2A3 duplication could be due to
posttranscriptional or posttranslational modifications that may be
necessary for the organism to flexibly adapt to changes in glucose
supply and demand. An increase in GLUT3 protein half‐life was de-
scribed as a posttranslational mechanism in episodes of prolonged
energy demand (Khayat, McCall, & Klip, 1998). Further studies,
preferably in neuronal cell lines, should aim to elucidate whether
SLC2A3 gene duplication can also influence protein expression.
There are not many studies which have investigated whether
SLC2A3 CNVs can alter downstream metabolic pathways, and sys-
tematic analyses determining whether compensatory/transregulatory
expression changes in non‐GLUT genes may occur are lacking. An in-
itial study has reported reduced glycolytic activity in the immune cells
of deletion carriers (Simpfendorfer et al., 2019), which could poten-
tially lead to cellular growth restriction. Synaptic outgrowth has also
been observed reduced in murine neurons with SLC2A3 knockdown in
early postnatal development, supporting the role of GLUT3 as an im-
portant factor in neuronal maturation (Segarra‐Mondejar et al., 2018).
2.5 | Functional consequences of SLC2A3
expression changes in animal models
Slc2a3 KO mice models have been created by several working groups.
Heterozygosity leads to early pregnancy loss in approximately 25% of
affected mouse embryos (Ganguly et al., 2007), whereas a bi‐allelic de-
letion of Slc2a3 is deleterious, leading to abortion at Day 12 p.c. It has
therefore been suggested that GLUT3‐mediated glucose uptake is pi-
votal for organogenesis (Schmidt et al., 2009). Slc2a3+/− mice do not
differ from WT animals in feeding behavior, body weight, blood‐glucose,
or insulin concentrations. However, electrophysiology has demonstrated
that Slc2a3+/− mice exhibit overall increased cerebrocortical activity, and
an increased startle response to acoustic stimuli (Schmidt et al., 2008).
Zhao et al. (2010) additionally described reduced vocalization, motor
stereotypies, increased epileptic activity in electroencephalography
(EEG) recordings with rare tonic posturing and motor arrests, and im-
paired spatial learning and working memory. These features caused the
authors to classify the symptoms as an autism‐like phenotype.
Recently, a conditional tissue‐specific postnatal Slc2a3−/− KO
mouse was designed, permitting normal embryonal development
(Shin et al., 2018). In the neural‐specific KO, the animals died be-
tween Day 15 and 31 after genetic manipulation. They showed di-
minished brain weight, reduced cortical thickness, and reduction of
dendritic spines, as well as fewer ultrasonic vocalizations. Electro-
physiological recordings also suggested cortical hyperexcitability.
When KO was restricted to the adult male limbic system normal
survival was observed, but coincided with reduced locomotor activ-
ity, reduced grip strength and body tone, reduced coordination skills,
and impaired spatial learning. Fear conditioning tests and the open‐
field test also implied reduced fear responses and less caution in
social interactions when testing social novelty (Shin et al., 2018).
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Taken together, characterization of the different Slc2a3 KO
mouse models supports the notion that GLUT3 plays an important
role in brain electrochemical balance. Loss‐of‐function may inhibit
synaptic plasticity in critical developmental stages, evoking cortical
hyperexcitability with increased risk for epileptic seizures, perturbed
social interactions, and impaired learning abilities (Shin et al., 2018;
Zhao et al., 2010). The novel findings of cortical hyperexcitability
both in constitutive and conditional SLC2A3 KO models (Shin
et al., 2018; Zhao et al., 2010) highlight the capacity of GLUT3 to
modulate excitatory synaptic plasticity, which is additionally in-
dicated by the close interaction of GLUT3‐mediated glucose supply
and neurotransmission in glutamatergic cell culture models (Figure 3)
(Ferreira et al., 2011; Weisova et al., 2009). Slc2a3 KO mice have so
far only been investigated for alterations in the CNS and the meta-
bolic system. However, other organ systems should also be assessed
in future studies. The development of a GLUT3 overexpression
mouse model would also further elucidate the potential molecular
and behavioral consequences of SLC2A3 duplication events, com-
plementing the already achieved insights from current KO‐
mouse data.
3 | SLC2A3 COPY NUMBER VARIATION
AND ASSOCIATED CLINICAL PHENOTYPES
3.1 | Neuropsychiatric disorders
In humans, the brain has the highest relative energy demand of any
organ, consuming up to 20% of the body's oxygen and glucose intake,
yet only accounting for 2% of the total bodily mass (Rolfe &
Brown, 1997). The majority of the brain's energy is needed for
neurotransmission; specifically, to restore the resting membrane
potential, which collapses when neurons fire (Harris, Jolivet, &
Attwell, 2012). Fatty acids cannot pass the blood‐brain barrier, and
therefore fatty acid oxidation cannot be used for ATP production in
the brain. However, during prolonged fasting periods, ketone bodies
can be used as alternative electron donors (Morris, 2005;
Owen, 2005). Additionally, a lactate‐shuttle from astrocytes to neu-
rons has been extensively discussed as an additional potential source
of neuronal energy supply. This mechanism enables transport of
lactate from anaerobic glycolysis of astrocytes to neurons via
monocarboxylate transporters MCT1/2/4 (Figure 3). Consequently,
neurons use this lactate for pyruvate synthesis to fuel TCA in aerobic
respiration (Mason, 2017; Pellerin, Pellegri, Bittar, Martin, & Magis-
tretti, 1998). Despite these other possible energy sources, it is still
widely accepted that under non‐fasting conditions the brain's energy
demand is primarily provided by glucose (Clarke & Sokoloff, 1999;
Lundgaard et al., 2015). Therefore alterations in GLUT3‐mediated
neuronal glucose uptake may have a large impact on the brain, and
warrant investigation as a potential pathomechanism in neu-
ropsychiatric disorders.
We first identified the SLC2A3 duplication in a genome‐wide
copy number variation analysis in an extended pedigree of patients
with ADHD as an inherited variant (Lesch et al., 2011). In a con-
secutive case‐control study we found a significant over-
representation of the duplication in our German child and adult
ADHD sample, but not in the Spanish and Dutch replication samples.
In a meta‐analysis of all three samples, a significant additive effect of
SLC2A3 copy number and a single nucleotide polymorphism (SNP) in
the SLC2A3 3′‐untranslated region was identified, suggesting a syn-
thetic association of the common SNP variant with the more rare
CNVs. We therefore hypothesized that SLC2A3 duplication‐asso-
ciated ADHD risk is dependent on genetic background, in a popula-
tion‐specific manner. On the endophenotypic level, duplication
carriers underestimated the amount of calories in high‐caloric food.
Furthermore, we found an influence of the duplication variant on
EEG‐measured event‐related potentials in neurocognitive tasks.
These tasks comprised a continuous performance test (Go‐NoGo
paradigm) and an n‐back task, which represent measures of cognitive
response control as a frontal capacity and working memory perfor-
mance, respectively. Our results suggest that SLC2A3 duplication
variants may alter neural processing in tasks requesting cognitive
efforts (Merker et al., 2017). The potential mechanisms behind this
finding are currently unclear, but hypothetically could be related to
impaired emotional decision‐making as a prefrontal function of al-
tered reward‐related circuits, in concordance with the frontostriatal
network hypothesis of ADHD (for review, see Cubillo, Halari, Smith,
Taylor, & Rubia, 2012). Considering the neurodevelopmental nature
of ADHD, fluctuating SLC2A3 expression that correlates with axonal
sprouting and pruning (Khan, Rajakumar, McKnight, Devaskar, &
Devaskar, 1999; Vannucci, 1994), and the severe stunting observed
in homozygous KO mice (Shin et al., 2018), it is a plausible option that
alterations in SLC2A3 gene dosage interfere with neurodevelopment.
This may not only apply to ADHD, but also to other neuropsychiatric
disorders with a significant genetic contribution, such as schizo-
phrenic psychosis and bipolar disorder. For the former, altered glu-
cose metabolism was found in the striatum with reduced TCA and
consequently enhanced anaerobic glycolytic activity (Dean, Thomas,
Scarr, & Udawela, 2016). Supporting the latter, in an Amish pedigree
family a diagnosis of bipolar disorder was observed in approximately
50% of SLC2A3 gene duplication carriers (Yang et al., 2009).
Besides the potential impact of GLUT3‐mediated glucose uptake
for neurodevelopmental disorders, alterations in GLUT3 expression
have also been associated with neurodegenerative disorders, such as
Alzheimer's(AD) and Huntington's disease (HD). Decreased GLUT3
expression levels in post‐mortem brain tissue was observed for both
diseases (Covarrubias‐Pinto et al., 2015; Gamberino & Bren-
nan, 1994; Liu, Liu, Iqbal, Grundke‐Iqbal, & Gong, 2008). Decreased
GLUT3 and GLUT1 protein levels have been associated with Tau
hyperphosphorylation and neurofibrillary tangle load, implying a
possible link between impaired brain glucose metabolism and AD (Liu
et al., 2008; Simpson, Chundu, Davies‐Hill, Honer, & Davies, 1994).
Reduced GLUT expression has been associated with a decrease in
HIF1α in the brain of patients with AD (Liu et al., 2008). Conversely,
mounting evidence suggests a crucial role of the PI3K/Akt pathway
with mTOR hyperactivation for the formation of senile plaques and
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neurofibrillary tangles (Tramutola et al., 2015). However, increased
mTOR signaling would result in enhanced glycolytic activity and
GLUT3 expression via HIF1α (Figure 2). This apparent contradiction
might be explained by an as yet unknown mechanism of SLC2A3
downregulation despite HIF1α activation, or a general deficit in
protein synthesis caused by oxidative stress in late‐stage neurode-
generative processes (Dasuri, Zhang, & Keller, 2013). Overexpression
of p53 was also been repeatedly found in various neurodegenerative
disorders (Morrison & Kinoshita, 2000), and could possibly be re-
sponsible for decreased GLUT3 levels, if p53 can evade negative
regulation via the PI3K/Akt pathway (Figure 2).
In HD the SLC2A3 duplication has been associated with a later
age of onset (Vittori et al., 2014). Glucose hypometabolism precedes
cell decline and is already detectable in premanifest patients with HD
(Ciarmiello et al., 2006), supporting the view that alterations in
neuronal glucose metabolism are not only a result of advanced
neurodegenerative cell damage but rather contribute to the patho-
physiology in some way. Hence, a reduction in GLUT3‐mediated
neuronal glucose uptake seems to be a common feature of neuro-
degenerative diseases, and initial evidence suggests a protective ef-
fect of the SLC2A3 duplication variant for HD (Vittori et al., 2014).
This is possibly due to a larger glucose transport capacity, confering
metabolic resistance against oxidative stress. However, the potential
role of glucometabolic changes in neurodegeneration should not be
overestimated, as these changes may just be a side‐effect of causa-
tive pathophysiological changes. Current CNV GWAS have so far not
associated SLC2A3 CNVs with AD (Swaminathan et al., 2012) or age
of onset of AD (Szigeti et al., 2014). However, the data has indirectly
suggested a genetic association between SLC2A3 and AD; an intronic
SNP rs10845990 in the neighboring SLC2A14 gene was among the
12 top hits (though not genome‐wide significant), with the G‐allele
conferring higher risk for AD (Shulman et al., 2011). This finding was
replicated in a subsequent case‐control study within a different po-
pulation (Wang et al., 2012). A database search on expression
quantitative trait loci derived from whole blood (www.eqtlgen.org)
shows that the rs10845990 G‐allele is not only associated with lower
SLC2A14 expression, but also with lower SLC2A3 and higher C3AR
expression levels (Võsa et al., 2018). C3AR encodes a complement
receptor whose brain expression correlates with cognitive decline in
humans, and which has been associated with Tau pathology in a
mouse model (Litvinchuk et al., 2018). Therefore, the functionality of
the SLC2A14 Alzheimer risk SNP might be due to cis‐regulation of
SLC2A3 and C3AR, thereby connecting possible glucometabolic dys-
regulation and complement‐mediated neuroinflammation in neuronal
cell damage.
Taken together, current findings indicate the relevance of
GLUT3 for neurodevelopmental and neurodegenerative processes.
Future research should focus on consequences of SLC2A3 over-
expression and deletion for neuronal glucose uptake, and determine
whether there are downstream cellular signaling targets which de-
pend on SLC2A3 gene dosage. It should be emphasized that no human
studies have so far associated SLC2A3 deletion variants with neu-
ropsychiatric disorders, and our own control cohorts include several
adult patients without any obvious symptoms of a neuropsychiatric
disorder that are also carriers of heterozygous SLC2A3 deletion.
3.2 | Cardiovascular diseases
The human heart is versatile in its ability to oxidize different energy
substrates, including glucose, fatty acids, ketone bodies, lactate and
amino acids. It is therefore less dependent on glucose metabolism
than the brain. Due to its vital hemodynamic role and scarce ATP
storage capacity, which only provides enough ATP for several beats,
the heart depends on a steady supply of substrate fuels
(Grynberg, 2005). This energy supply is mainly provided by fatty acid
oxidation, accounting for up to 70% total energy under normal
physiological conditions in healthy adults (Opie, 1991). Although
GLUT4 and GLUT1 are thought to be the primary cardiac GLUTs in
humans and rodents (Grover‐McKay et al., 1999; Kraegen
et al., 1993), GLUT3 is also expressed in the human heart: In fetal
cardiomyocytes, GLUT3 expression increases from Week 10–15, and
then subsequently decreases until Week 21 gestational age (Grover‐
McKay et al., 1999). This suggests an important role for GLUT3 in
cardiogenesis. Supporting this, a recent study found that SLC2A3
mRNA expression in fetal myocardium was 15.6‐fold higher than in
newborns (Kong, Liu, & Lu, 2008). These changes in expression may
reflect the switch from prenatal anaerobic glycolysis to postnatal
fatty acid oxidation as a preferential source of ATP generation
(Ascuitto & RossAscuitto, 1996).
SLC2A3 duplication has been repeatedly associated with con-
genital syndromic heart defects, including in Turner syndrome
(Prakash et al., 2016) and 22q11.2 deletion syndrome (Mlynarski
et al., 2015). In the latter, it was suggested that increased gene do-
sage might interact with genes in the 22q11.2 region, increasing risk
in a “two hit model” (Mlynarski et al., 2015). These findings are
supported by the increased maternal serum glucose levels observed
in tetralogy of Fallot (Priest, Yang, Reaven, Knowles, & Shaw, 2015).
These data, combined with the knowledge that mature heart for-
mation requires strict regulation of energy for normal cell guidance
and proliferation (Kloesel, DiNardo, & Body, 2016), suggest a path
from impaired glucose metabolism to cardiac misdevelopment. An
alternative hypothesis for the markedly increased frequency of
SLC2A3 duplication in congenital heart defects would be a gain‐of‐
function effect due to improved energetic supply, perhaps promoting
survival in the face of otherwise lethal cardiac development
impairments.
There are currently no studies demonstrating an association of
SLC2A3 CNVs with coronary heart disease, postischemic outcomes,
or cardiac remodeling resulting in ventricular hypertrophy. However,
overexpression of GLUTs has been demonstrated to have cardio-
protective effects post‐ischemia in mice (Luptak et al., 2007).
Furthermore, chronic hypertrophic stress has been observed to
cause a switch from fatty acid oxidation back to glycolysis as the
preferential source of ATP supply in cardiomycytes, similar to in the
fetus (Barger & Kelly, 1999). A beneficial effect of SLC2A3 duplication
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in cardiodegeneration therefore seems feasible, but is currently
lacking evidential support. Lastly, GLUT3 is also essential for the
secretory and aggregatory activity of platelets, and therefore may
potentially influence the development of atherosclerotic lesions
(Fidler, Middleton et al., 2017). In a mouse conditional double KO of
GLUT3 and GLUT1, reduced platelet activation and thrombogenic
potential was observed, suggesting a role of GLUT3 in thrombus
formation (Fidler, Campbell et al., 2017).
Taken together, the data suggests that SLC2A3 CNVs may have
an impact on cardiac development in syndromal disorders but sys-
tematic efforts to disentangle the role of glucometabolic alterations
in cardiovascular diseases are lacking. Therefore, current data war-
rants further investigation of the potential role of GLUT3 in cardio-
vascular diseases, particularly in cardiogenesis and ischemic heart
failure. As the heart relies on glycolytic energy exploitation only
under certain conditions, such as during cardiogenesis and hyper-
trophic stress, this might be a promising starting point for re-
searching the role of GLUT3‐mediated glucose supply in
developmental and degenerative heart disease.
3.3 | Immunodisorders
Activation of both the innate and adaptive immune systems is as-
sociated with increased proliferation, increased protein synthesis (for
antibody and chemokine production), cytoskeletal rearrangements
(for targeted cell migration), and enhanced secretory activity. These
cellular changes cause a rapid increase in energy demand, as de-
monstrated by elevated glucose utilization in activated immune‐
competent cells (Calder, Dimitriadis, & Newsholme, 2007; News-
holme, Costa Rosa, Newsholme, & Curi, 1996). In response to this
increased energy demand, immune cells can upregulate their GLUT
expression (including GLUT3) by up to 6‐fold (Fu, Maianu, Melbert, &
Garvey, 2004; Maratou et al., 2007). This has also been demon-
strated in CD4+ T‐cells, which showed increased GLUT1 and GLUT3
expression followed by a concomitant elevation of glycolytic rate,
promoting T‐cell activation, survival and expansion of T‐effector cells
(Macintyre et al., 2014). Increased GLUT expression may represent a
general adaptive mechanism to high energetic demands, indirectly
reflecting disease activity under certain conditions. For example, in
autoimmune hepatitis disease activity appears to correlate with
enhanced glucose metabolism and strong GLUT3 expression in in-
flammatory IgG4+ cells (Araki et al., 2018). However, chronic
demyelinated lesions in multiple sclerosis conversely exhibit a re-
duction in axonal GLUT3 (Nijland et al., 2014), although this may
represent adaptation to a decreased energy demand following neu-
rodegenerative damage, rather than a direct response to a patho-
genic catalyst. It is currently unclear whether inflammatory activity
could potentially be decreased by reducing GLUT3‐mediated glucose
uptake in leukocytes. Further studies should aim to elucidate this
possibility, as it could potentially represent a novel therapeutic
approach for the treatment for immune system disease by GLUT
inhibition.
SLC2A3 CNV, specifically deletion, has been suggested to play a
role in autoimmune diseases. Frequency of SLC2A3 deletion was
found significantly lower in patients with RA than healthy controls
(odds ratio = 0.5) in a large study of a Swedish cohort, a finding which
could be replicated in two other samples, bringing the total cohort
number to 6124 cases (deletion frequency 0.78%) and 9511 controls
(deletion frequency 1.13%; Veal et al., 2014). These data suggest that
SLC2A3 may provide a protective effect against RA. However, in a
higher‐powered independent replication study, this association was
not observed (Simpfendorfer et al., 2019). Although initial results
may have been a false positive, it is also possible that there is a
population‐specific effect of SLC2A3 CNVs on different disease
phenotypes (Merker et al., 2017). Rare SNP variants, which have
been enriched in certain populations due to specific evolutionary
pressures, may explain this discrepancy in results and should be
further explored.
RA is caused by an incorrect response of both the innate and
adaptive immune systems, where proliferation of fibroblast‐like sy-
noviocytes and various immune cells (such as macrophages, mast
cells, lymphocytes, and neutrophils) results in inflammation of the
synovial membrane (Smolen, Aletaha, & McInnes, 2016). Garcia‐
Carbonell et al. (2016) demonstrated that these fibroblast‐like sy-
noviocytes from patients with RA are metabolically shifted towards
glycolysis, and that glucose deprivation could inhibit cytokine se-
cretion, cell proliferation and migration. Moreover, in a mouse model
of inflammatory arthritis, inhibition of glycolysis led to reduction in
arthritic inflammation.
These data strongly suggest that there are adaptive metabolic
changes in activated immune cells, to answer increased energy de-
mands. Furthermore, the SLC2A3 deletion variant may even act to
inhibit pathologic cell proliferation in RA via limitation of GLUT3‐
mediated glucose uptake, though evidence supporting a protective
effect of diminished glucose uptake in immunodisorders is sparse.
Further research determining the potential effect of SLC2A3 CNVs in
other immune system cell types, and additional functional studies
(e.g., inducing arthritis in GLUT3‐KO versus WT mice (Monach,
Mathis, & Benoist, 2008)) are necessary to support the hypothesis of
an SLC2A3 protective loss‐of‐function in immune diseases.
4 | CONCLUSION: HOW MANY SLC2A3
GENE COPIES ARE “ IDEAL”?
As a high affinity glucose transporter GLUT3 plays an essential role
in providing energetic fuel for both neurons and several other cell
types, which require either a consistently high or rapidly alternating
ATP supply due to specific functions. Cellular functions potentially
affected by GLUT3‐dependent energy supply include the recon-
stitution of resting membrane potentials in neurons, cardiomyocytes,
and the continuous cytoskeletal rearrangements for lymphocyte
migration in immune reactions. Furthermore, GLUT3 contributes to
the Warburg effect, as it helps to answer the cancer cell's increased
glucose demand. Even though SLC2A3 CNVs may not cause disease in
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a mendelian inheritance pattern, the combined data suggests that
they likely contribute to pathological activity in several clinical dis-
orders. Pathological conditions with mitochondrial dysfunction and
alterations in ATP demand are therefore of particular interest. Due
to the increased energy demand during organogenesis and altered
GLUT expression profiles in cell decline, we suggest putting a focus
both on developmental and degenerative diseases in upcoming in-
vestigations. Future studies assessing the association between
SLC2A3 CNVs and disease should be well‐powered and in-
dependently replicated, especially as the frequency of SLC2A3 copy
number alterations is low. Possible additive effects of SLC2A3 CNVs
and polygenic risk load of common SNPs should also be considered,
to include the impact of any gene‐gene interactions.
Alterations in SLC2A3 gene dosage appear to have the ability to
be beneficial or deleterious depending on the specific situation, in-
fluencing disease risk, progression, and prognosis. Distinct examples
are the delayed age of onset of HD in SLC2A3 duplication carriers,
and the worse survival outcome of cancer patients with GLUT3
overexpressing tumors. Whereas the former highlights the degen-
erating neuron's vital dependence on GLUT3‐mediated glucose sup-
ply, the latter illustrates the cancer cell's high glucose requirements,
with GLUT overexpression facilitating invasive tumor growth and
metastases. These examples highlight the potential cellular con-
sequences of SLC2A3 CNVs for clinical outcomes, depending on tis-
sue‐specificity and individual pathological predisposition, reflecting a
modifying rather than a causative role of SLC2A3 CNVs for disease
activity. This is supported by the data which suggests that the
SLC2A3 gene is not particularly sensitive to loss‐of‐function muta-
tions ((pLI score = 0.01, gnomad.broadinstitute.org). There is there-
fore no general “ideal” SLC2A3 copy number. We suggest that
dynamic cellular processes, which rely on a high ATP supply, are
especially susceptible to alterations in SLC2A3 copy number. This
susceptibility may become apparent when energy demands alter due
to normal aging or pathological activity.
Additional SLC2A3 copies may convey advantageous effects in
disease conditions where energy metabolism becomes insufficient,
such as cellular degradation and hypertrophy, by increasing overall
glucose uptake capacity. In neurodevelopmental disorders, such as
ADHD or autism however, SLC2A3 CNVs could disturb highly en-
ergy‐dependent axonal organization and pruning during the for-
mation of neural networks. Similarly, SLC2A3 deletion may improve
disease states that are characterized by uncontrolled cell pro-
liferation (such as autoimmune diseases and neoplasms), yet po-
tentially intensify neurodegeneration. Embryonal differentiation,
organogenesis, maturation, cancer formation, and degenerative
processes in a broad range of organ systems, such as the CNS, heart,
and immune‐competent cells are therefore important targets for
future investigations.
To date, the majority of data is only correlational, with no de-
finitive cause‐and‐effect relationship between SLC2A3 gene dosage
and clinical phenotypes reported. Future studies should aim to
follow a multidimensional approach in an attempt to elucidate this
potential relationship. Such an approach requires the integration
of data from basic molecular biology, electrophysiology, neu-
ropsychology and imaging, to provide a clearer picture of the pos-
sible impacts of structural SLC2A3 variation. With development of
an SLC2A3 overexpression mouse and the advent of induced
pluripotent stem cells (Jansch et al., 2018) there will be two new
models available to study the influence of SLC2A3 CNVs on both the
molecular and behavioral level.
Finally, the designation of GLUT3 as a “neuronal glucose trans-
porter” may have led to its role in peripheral tissues being over-
looked. However, newly identified associations between SLC2A3
CNVs and various clinical disorders demonstrate that GLUT3‐medi-
ated bioenergetic imbalances may be important in a range of tissue
types, reflecting a broad spectrum of diseases. This research avenue
is of high relevance not only due to general interest in glucometabolic
pathomechanisms, but also due to the potential of GLUTs as pro-
mising novel therapeutic targets.
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